https://www.sciencedirect.com/science/article/pii/S0166354220302011
"Although several
clinical trials are now underway to test possible
therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that
Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity
in vitro, is an inhibitor of the causative
virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in
viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans."